Pegylated Interferon-α2b

Phase 2Terminated
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Aug 11, 2020 → Jun 21, 2021

About Pegylated Interferon-α2b

Pegylated Interferon-α2b is a phase 2 stage product being developed by Zydus Lifesciences for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT04480138. Target conditions include Covid19.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04480138Phase 2Terminated